# Sahajanand Medical technologies Limited: IPO analysis > Sahajanand Medical technologies Limited (CIN U33119GJ2001PLC040121) has filed a Red Herring Prospectus with SEBI for an IPO comprising an offer for sale of 1.38 Cr shares, priced at ₹327.00 to ₹344.00 per share. In FY26 it reported revenue of ₹1,211 Cr and a net profit of ₹69 Cr. Promoters hold 36.7% before the IPO. Our fact-check of its claims found no medium or high concerns across 40 claims checked. - Page: https://ipo.innerkore.com/company/U33119GJ2001PLC040121/sahajanand-medical-technologies-limited/ - CIN: U33119GJ2001PLC040121 - Last updated: 10 Oct 2026 ## Key facts - **Company:** Sahajanand Medical technologies Limited - **CIN:** U33119GJ2001PLC040121 - **Filing stage:** RHP - **Latest SEBI filing:** 10 Oct 2026 - **Offer for sale:** 1,38,22,116 shares - **Price band:** ₹327.00 to ₹344.00 per share - **Bidding opens:** 15 Oct 2026 - **Bidding closes:** 19 Oct 2026 - **Listing on:** BSE, NSE - **Revenue FY26:** ₹1,211 Cr - **Net profit FY26:** ₹69 Cr - **Promoter holding (pre-IPO):** 36.7% - **Lead managers:** Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, Nuvama Wealth Management Limited - **Registrar:** MUFG Intime India Private Limited - **Fact-check flags:** 0 high, 0 medium, 0 low ## Key signals (read from the filing; not investment advice) - **Valuation** (concern): 50.6x P/E. From NSE's price band, on FY26 profit; 5x book value. - **Profitability** (look closer): 5.7% net margin. FY26. - **Debt** (looks fine): 0.38x equity. ₹270 crore borrowed at the end of FY26. - **Profit into cash** (looks fine): 152% of profit. Operations brought in ₹105 crore against ₹69.1 crore of profit in FY26. - **One-off income** (look closer): 10% of profit. Other and one-off income is 10% of pre-tax profit. - **Where the money goes** (concern): All for sale. Entirely an offer for sale: the company receives nothing. - **Red flags** (looks fine): None serious. 40 claims checked: 0 high, 0 medium concern. ## Financial snapshot (₹ crore unless stated; consolidated) | | 3M Jun-24 | 3M Jun-25 | FY26 | 3M Jun-26 | |---|---:|---:|---:|---:| | Sales | 902 | 1,025 | 1,211 | 352 | | Operating profit | 110 | 128 | 171 | 49 | | Operating margin | 12.2% | 12.5% | 14.1% | 13.8% | | Net profit | -7.4 | 25 | 69 | 15 | | Net margin | -0.8% | 2.5% | 5.7% | 4.3% | | Net worth | – | – | 702 | 717 | | Borrowings | – | – | 270 | 321 | | Return on equity | – | – | 9.8% | – | ## Fact-checked claims - **NONE** (PromoterBackground): The Shree Hari Trust (SHT) was formed as a private family trust by the late Vallabhbhai Kotadia.. No web search results were found for the claim regarding the formation of the Shree Hari Trust (SHT) by the late Vallabhbhai Kotadia. Therefore, no corroboration or contradiction could be assessed. - **NONE** (PromoterBackground): Priyanka Dhirajlal Cohen is one of the Promoters and serves as a Non-Executive Director of the Company.. No current web search results were found to corroborate, contradict, or provide any information regarding the claim that Priyanka Dhirajlal Cohen is a Promoter and Non-Executive Director of Sahajanand Medical technologies Limited. - **NONE** (PromoterBackground): Dhirajlal Vallabhbhai Kotadia is one of the Promoters and serves as the Chairman Emeritus and Non-Executive Director of the Company.. No current web search results were found to corroborate, contradict, or provide any information regarding the claim that Dhirajlal Vallabhbhai Kotadia is a Promoter, Chairman Emeritus, and Non-Executive Director of Sahajanand Medical technologies Limited. - **NONE** (PromoterBackground): Bhargav Dhirajlal Kotadia is one of the Promoters and serves as the Managing Director and Chief Executive Officer of the Company.. No current web search results were found to corroborate, contradict, or provide any information regarding the claim that Bhargav Dhirajlal Kotadia is a Promoter, Managing Director, and CEO of Sahajanand Medical technologies Limited. - **NONE** (PromoterBackground): The Promoters collectively hold 3,73,14,589 Equity Shares, representing 36.71% of the pre-Offer issued, subscribed and paid-up Equity Share capital on a fully diluted basis.. No web search results were found to corroborate, contradict, update, or provide any information regarding the claim made about the promoters' equity holdings in Sahajanand Medical technologies Limited. - **NONE** (PromoterBackground): Bhargav Dhirajlal Kotadia is the Managing Director and Chief Executive Officer.. No current web search results were found to corroborate or contradict the claim that Bhargav Dhirajlal Kotadia is the Managing Director and Chief Executive Officer of Sahajanand Medical technologies Limited. - **NONE** (PromoterBackground): Jose Calle Gordo is the Chairperson and Non-Executive Director.. No current web search results were found to corroborate, contradict, or provide any information regarding the claim that Jose Calle Gordo is the Chairperson and Non-Executive Director of Sahajanand Medical technologies Limited. - **NONE** (PromoterBackground): The Board comprises eight Directors as of the date of the Red Herring Prospectus, including one Executive Director, three Independent Directors, and four Non-Executive Directors.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the composition of the Board of Sahajanand Medical technologies Limited as described in the claim. - **NONE** (PromoterBackground): The Company has not declared or paid any dividend on the Equity Shares during the last three fiscal years, the three months ended June 30, 2026, and from July 1, 2026, till the date of this Red Herring Prospectus.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim about the declaration or payment of dividends by Sahajanand Medical technologies Limited. - **NONE** (PromoterBackground): The dividend distribution policy of the Company was approved and adopted by the Board on May 29, 2025.. No web search results were found to corroborate, contradict, update, or provide any information regarding the claim that the dividend distribution policy was approved and adopted by the Board on May 29, 2025. - **NONE** (PromoterBackground): Bhargav Dhirajlal Kotadia was appointed as Chief Executive Officer on April 1, 2025.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim that Bhargav Dhirajlal Kotadia was appointed as CEO on April 1, 2025. - **NONE** (PromoterBackground): Gaurav Goel was promoted to Chief Commercial Officer on April 1, 2025.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim that Gaurav Goel was promoted to Chief Commercial Officer on April 1, 2025. ## Common questions ### How big is the Sahajanand Medical technologies Limited IPO? Sahajanand Medical technologies Limited's IPO comprises an offer for sale of 1.38 Cr shares, according to its Red Herring Prospectus. The price band is ₹327.00 to ₹344.00 per share. ### What are Sahajanand Medical technologies Limited's revenue and profit? Sahajanand Medical technologies Limited reported revenue from operations of ₹1,211 Cr in FY26. Net profit was ₹69 Cr. Figures are read from the RHP, as printed there. ### How much do promoters own in Sahajanand Medical technologies Limited? Promoters hold 36.7% of Sahajanand Medical technologies Limited before the IPO. Largest holders listed: Shree Hari Trust# (36.8%); 5,000 Negligible@ [●] [●] [●] [●] 2. Shree Hari Trust**^^ (36.7%); Samara Capital Markets Holding Limited (31.4%). ### What are the red flags in Sahajanand Medical technologies Limited's RHP? We fact-checked 40 claims from the filing against the open web: 0 raised a high concern, 0 medium and 0 low. This is an automated screen, not a verdict; each finding links to its sources. ### What does Sahajanand Medical technologies Limited do? Here's what you need to know before investing in Sahajanand Medical technologies Limited's IPO. ### Who manages the Sahajanand Medical technologies Limited IPO? Book running lead managers: Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, Nuvama Wealth Management Limited. Registrar to the offer: MUFG Intime India Private Limited. Shares are proposed to list on BSE and NSE. ### Where can I read the original Sahajanand Medical technologies Limited IPO documents? All 1 filing for Sahajanand Medical technologies Limited (RHP) are listed on this page with links to the original PDFs on SEBI's website. Every page reference cites the exact page of the source document. ## Source documents - [Sahajanand Medical technologies Limited – RHP](https://www.sebi.gov.in/sebi_data/attachdocs/oct-2026/1791785603861.pdf) (Red Herring Prospectus, filed 10 Oct 2026) --- Source: InnerKore IPO (https://ipo.innerkore.com/). Read from public SEBI filings by automated extraction; check the linked documents. Not investment advice.